Micro data assessment of Russian drug benefit monetization

Besstremyannaya, Galina

doi:10.1108/14777260910983970

Cited by 3 publications

(18 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty‐eight articles were obtained from the database searches. Based on a preliminary review of the abstracts, 18 articles were excluded because they were not original economic analyses [17–34] . The remaining 20 articles were then located and the full articles were evaluated to determine if they met the study criteria.…”

Section: Resultsmentioning

confidence: 99%

“…Based on a preliminary review of the abstracts, 18 articles were excluded because they were not original economic analyses. [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] The remaining 20 articles were then located and the full articles were evaluated to determine if they met the study criteria. After reviewing the full articles, one article was excluded because it was not on Russia [35] and three were excluded because they were not original economic analyses.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The state of health economics and pharmaceoconomics research in Russia: a systematic review

Gavaza

Shepherd

Shcherbakova

et al. 2010

Journal of Pharmaceutical Health Services Research

View full text Add to dashboard Cite

Objectives To investigate the state of health economic research in Russia available in the English language by describing the number and characteristics of the articles, and assessing the quality of these articles. Methods The study assessed the state of health economics and pharmacoeconomics research in Russia. We conducted a literature search to identify health economics articles pertaining to Russia. Each article in the final sample was scored by two reviewers independently using the data‐collection form designed for the study. Key findings In total, 16 studies investigating a wide variety of diseases were included in the study. These articles were published in 15 different journals all based outside of Russia between 1994 and 2009. On average, each article was written by seven authors. Most first authors had medical/clinical training and resided in the USA (n = 8) at the time of publication of the study. Based on a scale of 1–10, with 10 indicating the highest quality, the mean quality score for all studies was 8.09 (SD = 1.29) and 25% of the articles were of fair quality (score 5–7). The quality of articles was statistically significantly related (P < 0.05) to the primary health intervention (pharmaceuticals > non‐pharmaceuticals) and primary training of the first author (medical > non‐medical). Conclusions The conduct of health economics and pharmacoeconomics research in Russia in the English language is limited and, on average, the published articles were of good quality. However, about one‐quarter of published articles were of fair quality. More health economics research in English is warranted in Russia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The state of health economics and pharmaceoconomics research in Russia: a systematic review

Gavaza

Shepherd

Shcherbakova

et al. 2010

Journal of Pharmaceutical Health Services Research

View full text Add to dashboard Cite

show abstract

“…The standard solution to the adverse selection problem is to recommend a mandatory insurance scheme (Pauly and Zeng 2004), but in Russia and other emerging economies the feasibility and popularity of this solution is low. Indeed, Russia's program of social welfare monetization in 2005 represents a salutary lesson in this regard (Besstremyannaya 2009). Second, while the evidence is relatively weak, the data does suggest that more affluent residents of the country are against joining voluntary drug insurance schemes for reasons which may reflect their existing private insurance or simply their confidence concerning the affordability of treatment in the event of illness.…”

Section: Discussion and Policy Recommendationsmentioning

confidence: 95%

Reforming voluntary drug insurance in Russian healthcare: does social solidarity matter?

2017

View full text Add to dashboard Cite

With low take-up of both private health insurance and the existing public drug reimbursement scheme, it is thought that less than 5% of the Russian population have access to free outpatient drug treatment. This represents a major policy challenge for a country grappling with reforms of its healthcare system and experiencing low or no economic growth and significant associated reductions in spending on social services. In this paper, we draw on data from a 2011 Levada-Center survey to examine the attitudes and social solidarity of the Russian population towards drug policies in general and towards the introduction of a proposed voluntary drug insurance system in particular. In addition to being among the first to explore these important questions in the post-Communist setting, we make three important contributions to the emerging policy debates. First, we find that, if introduced immediately and without careful planning and preparation, Russia's voluntary drug insurance scheme is likely to collapse financially due to the over-representation of high-risk unhealthy individuals opting in to the scheme. Second, the negative attitude of higher income groups towards the redistribution of wealth to the poor may further impede government efforts to introduce voluntary drug insurance. Finally, we argue that Russia currently lacks the breadth and depth of social solidarity necessary for implementing this form of health financing.

show abstract

“…employees of civil and armed services or those moving to strategically important or remote areas), but not based on income. As such, privileges were neither designed to serve as social assistance or relieve hardships, nor were they exclusively awarded to low-income consumers (Struyk et al, 2007;Wengle & Rasell 2008;Besstremyannaya, 2009b).…”

Section: The 2005 Social Benefits Reform In the Russian Federationmentioning

confidence: 99%

“…The changes brought by the reform affected millions of Russian beneficiaries, yet studies that evaluate and track effects of the reform during the extended post-reform period are still lacking. The studies that were conducted during the post-reform period mainly assessed the general design and reform implementation (Besstremyannaya, 2009b;Ovcharova, 2005;Volchkova et al, 2006;Alexandrova & Struyk, 2007;Sinitsina, 2009;Wengle & Rasell, 2008); reported on short-term adjustments that have arisen from the reform and its public perception (Besstremyannaya, 2009b;Hahulina, 2005;Alexandrova & Struyk, 2007;Struyk et al, 2007;Wengle & Rasell, 2008;Parfitt, 2007;Zasimova, 2010); and gave numerical estimations of benefit groups' behavior before and after the reform (Besstremyannaya, 2009b).…”

Section: Introductionmentioning

confidence: 99%

Financial reforms and out-of-pocket payments in the Russian healthcare sector

Gordeev¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Micro data assessment of Russian drug benefit monetization

Abstract: The paper represents an attempt to use a large sample statistical analysis along with the Federal Social Insurance Fund data in order to assess drug benefit groups of behavior in Russian regions before and after the drug benefit reform.

Cited by 3 publications

References 4 publications

The state of health economics and pharmaceoconomics research in Russia: a systematic review

The state of health economics and pharmaceoconomics research in Russia: a systematic review

Reforming voluntary drug insurance in Russian healthcare: does social solidarity matter?

Financial reforms and out-of-pocket payments in the Russian healthcare sector

Contact Info

Product

Resources

About